Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
Human immunodeficiency virus (HIV)-associated facial lipoatrophy (FLA) represents a common and highly stigmatizing side effect of retroviral therapy. By causing loss of subcutaneous adipose tissue mainly in the cheek, temple and periocular area, FLA can significantly affect the patient's quality of life, both physically and psychologically. A limited quantity of data has been published on various filling substances for the management of FLA. Here, the authors present two patients with HIV-associated FLA successfully treated with a novel HA filler over a period of 24 months.
Pavicic
Tatjana
T
Department of Dermatology, Ludwig-Maximillians-University, Munich, Germany. Tatjana.Pavicic@med.uni-muenchen.de
Ruzicka
Thomas
T
Korting
Hans-Christian
HC
Gauglitz
Gerd
G
D000328:Adult; D003432:Cross-Linking Reagents / Q000008:administration & dosage*; D005145:Face; D015658:HIV Infections / Q000150:complications*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged
D003432:Cross-Linking Reagents; D006820:Hyaluronic Acid